{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:13:42Z","timestamp":1792872822289,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n In recent decades, there has been increased interest in the possible adverse neurological effects of 5\u03b1-reductase inhibitors (5-ARIs), which have been used mainly for benign prostatic hyperplasia and androgenic alopecia. Numerous studies and reports have indicated associations of 5-ARIs with depression and suicide. However, most of these studies had methodological shortcomings, and very little is known about the potential association of 5-ARIs with dementia.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the association of 5-ARI use with all-cause dementia, Alzheimer disease, vascular dementia, depression, and suicide.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This Swedish register-based cohort study included 2\u202f236\u202f876 men aged 50 to 90 years between July 1, 2005, and December 31, 2018. Statistical analyses were performed from September 15, 2021, to May 25, 2022.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n A diagnosis of all-cause dementia, Alzheimer disease, vascular dementia, depression, or completed suicide.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n A recorded prescription in the Swedish national prescription register of finasteride or dutasteride and duration of use.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 2\u202f236\u202f876 men (median age at the start of follow-up, 55 years [IQR, 50-65 years] and at treatment initiation, 73 years [IQR, 66-80 years]), 70\u202f645 (3.2%) started finasteride treatment, and 8774 (0.4%) started dutasteride treatment. Men taking finasteride or dutasteride were at increased risk of all-cause dementia (finasteride: hazard ratio [HR], 1.22 [95% CI, 1.17-1.28]; dutasteride: HR, 1.10 [95% CI, 1.01-1.20]), Alzheimer disease (finasteride: HR, 1.20 [95% CI, 1.10-1.31]; dutasteride: HR, 1.28 [95% CI, 1.09-1.50]), vascular dementia (finasteride: HR, 1.44 [95% CI, 1.30-1.58]; dutasteride: HR, 1.31 [95% CI, 1.08-1.59]), and depression (finasteride: HR, 1.61 [95% CI, 1.48-1.75]; dutasteride: HR, 1.68 [95% CI, 1.43-1.96]). However, the magnitude of the association decreased over time, and the findings became statistically nonsignificant with continuous exposures over 4 years, except for depression, which showed a constant risk over time, with no differences between finasteride and dutasteride. In contrast, 5-ARIs were not associated with suicide (finasteride: HR, 1.22 [95% CI, 0.99-1.49]; dutasteride: HR, 0.98 [95% CI, 0.62-1.54]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study found that, while men receiving 5-ARI treatment showed a higher risk for dementia in the initial periods after starting treatment, the decreasing magnitude of the association over time suggested that the risk may be, entirely or in part, due to increased dementia detection among patients with benign prostate enlargement. Both finasteride and dutasteride were similarly associated with depression with a constant risk over time, while neither drug was associated with suicide. Prescribing clinicians and potential users should be aware of the possible risks for depression associated with 5-ARI use.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.48135","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T11:33:55Z","timestamp":1671708835000},"page":"e2248135","source":"Crossref","is-referenced-by-count":58,"title":["Association of 5\u03b1-Reductase Inhibitors With Dementia, Depression, and Suicide"],"prefix":"10.1001","volume":"5","author":[{"given":"Miguel","family":"Garcia-Argibay","sequence":"first","affiliation":[{"name":"Clinical Epidemiology and Biostatistics, School of Medical Sciences, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Hiyoshi","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Biostatistics, School of Medical Sciences, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"},{"name":"Department of Public Health Sciences, Stockholm University, Stockholm, Sweden"},{"name":"Department of Epidemiology and Public Health, University College London, London, United Kingdom"},{"name":"Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Fall","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Biostatistics, School of Medical Sciences, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Biostatistics, School of Medical Sciences, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"},{"name":"Department of Epidemiology and Public Health, University College London, London, United Kingdom"},{"name":"Clinical Epidemiology Division, Department of Medicine, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"issue":"9","key":"zoi221361r1","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1158\/1055-9965.EPI-10-0082","article-title":"Knowledge and use of finasteride for the prevention of prostate cancer.","volume":"19","author":"Hamilton","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"zoi221361r3","first-page":"S31","article-title":"Comparison of clinical trials with finasteride and dutasteride.","volume":"6","author":"Nickel","year":"2004","journal-title":"Rev Urol"},{"issue":"6","key":"zoi221361r4","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1210\/jc.2015-1016","article-title":"Longitudinal relationships between reproductive hormones and cognitive decline in older men: the Concord Health and Ageing in Men Project.","volume":"100","author":"Hsu","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"zoi221361r5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1210\/jcem.84.2.5495","article-title":"Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study.","volume":"84","author":"Barrett-Connor","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"zoi221361r6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/pcan.2017.10","article-title":"Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.","volume":"20","author":"Nead","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"zoi221361r7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.urology.2018.06.022","article-title":"A review of the FAERS data on 5-alpha reductase inhibitors: implications for postfinasteride syndrome.","volume":"120","author":"Baas","year":"2018","journal-title":"Urology"},{"issue":"3","key":"zoi221361r8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1557988314538445","article-title":"Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms.","volume":"9","author":"Ganzer","year":"2015","journal-title":"Am J Mens Health"},{"key":"zoi221361r9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jns.2017.05.064","article-title":"The risk of dementia with the use of 5 alpha reductase inhibitors.","volume":"379","author":"Welk","year":"2017","journal-title":"J Neurol Sci"},{"issue":"3","key":"zoi221361r10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11255-015-0920-5","article-title":"Depressive symptoms in patients diagnosed with benign prostatic hyperplasia.","volume":"47","author":"Pietrzyk","year":"2015","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"zoi221361r11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw168","article-title":"Long-term consequences of finasteride vs placebo in the Prostate Cancer Prevention Trial.","volume":"108","author":"Unger","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"zoi221361r12","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.4088\/JCP.12m07887","article-title":"Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects.","volume":"73","author":"Irwig","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"zoi221361r13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-6904-6-7","article-title":"Finasteride induced depression: a prospective study.","volume":"6","author":"Rahimi-Ardabili","year":"2006","journal-title":"BMC Clin Pharmacol"},{"issue":"7","key":"zoi221361r14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/phar.1612","article-title":"Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study.","volume":"35","author":"Ali","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"5","key":"zoi221361r15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamainternmed.2017.0089","article-title":"Association of suicidality and depression with 5a-reductase inhibitors.","volume":"177","author":"Welk","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"6","key":"zoi221361r16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1159\/000505151","article-title":"Finasteride and suicide: a postmarketing case series.","volume":"236","author":"Irwig","year":"2020","journal-title":"Dermatology"},{"issue":"1","key":"zoi221361r17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jamadermatol.2020.3385","article-title":"Investigation of suicidality and psychological adverse events in patients treated with finasteride.","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"2","key":"zoi221361r18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1515\/HMBCI.2010.010","article-title":"The influence of low dose finasteride, a type II 5a-reductase inhibitor, on circulating neuroactive steroids.","volume":"1","author":"Du\u0161kov\u00e1","year":"2010","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"2","key":"zoi221361r19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pnpbp.2004.11.001","article-title":"Steroids, neuroactive steroids and neurosteroids in psychopathology.","volume":"29","author":"Dubrovsky","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"zoi221361r20","doi-asserted-by":"publisher","journal-title":"JAMA","DOI":"10.1001\/jama.2013.281053"},{"issue":"11","key":"zoi221361r21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"zoi221361r22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086215","article-title":"Drug-related problems in patients with benign prostatic hyperplasia: a cross sectional retrospective study.","volume":"9","author":"Zaman Huri","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"zoi221361r23","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.05.021","article-title":"Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations.","volume":"121","author":"Hoke","year":"2008","journal-title":"Am J Med"},{"issue":"4","key":"zoi221361r25","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1212\/01.WNL.0000134604.48018.97","article-title":"Sensitivity and specificity of dementia coding in two Swedish disease registries.","volume":"63","author":"Jin","year":"2004","journal-title":"Neurology"},{"issue":"2","key":"zoi221361r26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/JU.0000000000000209","article-title":"a-Blocker and risk of dementia in patients with benign prostatic hyperplasia: a nationwide population based study using the National Health Insurance Service database.","volume":"202","author":"Tae","year":"2019","journal-title":"J Urol"},{"issue":"1","key":"zoi221361r27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios.","volume":"21","author":"Hern\u00e1n","year":"2010","journal-title":"Epidemiology"},{"issue":"7","key":"zoi221361r28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/gps.v26.7","article-title":"Hypertension is a potential risk factor for vascular dementia: systematic review.","volume":"26","author":"Sharp","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"issue":"9","key":"zoi221361r30","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jcem.86.9.7821","article-title":"A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency.","volume":"86","author":"Ly","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"zoi221361r31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.maturitas.2011.05.012","article-title":"Testosterone levels and cognition in elderly men: a review.","volume":"69","author":"Holland","year":"2011","journal-title":"Maturitas"},{"issue":"12","key":"zoi221361r32","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.tins.2012.09.005","article-title":"The Allen Human Brain Atlas: comprehensive gene expression mapping of the human brain.","volume":"35","author":"Shen","year":"2012","journal-title":"Trends Neurosci"},{"issue":"D1","key":"zoi221361r33","doi-asserted-by":"publisher","first-page":"D996","DOI":"10.1093\/nar\/gks1042","article-title":"Allen Brain Atlas: an integrated spatio-temporal portal for exploring the central nervous system.","volume":"41","author":"Sunkin","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"zoi221361r34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.yhbeh.2012.04.006","article-title":"Gender, sex steroid hormones, and Alzheimer\u2019s disease.","volume":"63","author":"Vest","year":"2013","journal-title":"Horm Behav"},{"key":"zoi221361r35","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.psyneuen.2009.08.009","article-title":"Neurosteroids: endogenous allosteric modulators of GABAA receptors.","volume":"34","author":"Lambert","year":"2009","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"zoi221361r36","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1073\/pnas.95.6.3239","article-title":"Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine.","volume":"95","author":"Uzunova","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"zoi221361r37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coph.2008.12.006","article-title":"SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake.","volume":"9","author":"Pinna","year":"2009","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"zoi221361r38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/cns.2006.12.issue-1","article-title":"A new look at the 5a-reductase inhibitor finasteride.","volume":"12","author":"Finn","year":"2006","journal-title":"CNS Drug Rev"},{"key":"zoi221361r39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register.","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"zoi221361r2","volume-title":"Integrative Medicine","author":"Rakel","year":"2017","edition":"4th ed"},{"key":"zoi221361r29","first-page":"150","volume-title":"Frontiers of Hormone Research","author":"Cherrier","year":"2008"},{"key":"zoi221361r24","unstructured":"R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Published 2020. Accessed November 20, 2022. https:\/\/www.r-project.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2799858\/garciaargibay_2022_oi_221361_1671050388.85954.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T07:17:16Z","timestamp":1701587836000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2799858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.48135","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]}}}